Boehringer Ingelheim gets CDSCO panel nod to market Jardiance for additional indication
In a significant development, drug-major Boehringer has got a go ahead from the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization (CDSCO) to market its popular diabetes drug empagliflozin for an additional indication to reduce the risk of cardiovascular death plus hospitalisation for heart failure in adults with heart failure and reduced ejection fraction in adults.
This nod came after the firm presented the USFDA approval details for Empagliflozin Tablets 10/25mg as a new indication to reduce the risk of cardiovascular death plus hospitalisation for heart failure in adults with heart failure and reduced ejection fraction, in light of the SEC recommendation dated 09.03.2021 and 10.03.2021.
For more details, check out the full story on the link below:
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd